Revolut’s France Hub to Face ECB Constraints on New Lending
San Diego biotech Axiom Biosciences announced plans to become the first US biotech to list in Hong Kong, aiming to raise $150-200 million for its regenerative therapy pipeline. Its lead stem cell programme, developed with Korea's Medinno, showed no deaths among nine newborns with severe brain injuries in Phase 1.
DeFi Intel is an entity-graph aggregator: we curate, tag and link crypto news to a typed knowledge graph of protocols, tokens, people and incidents. We do not republish the full article body. Use the link above to read the original report at Bloomberg_crypto.
Entities in this story
Want the full article?
Continue reading on Bloomberg_crypto →